Scientists and clinicians around the world have been investigating various drug targets and potential therapeutics for COVID-19, the disease caused by SARS-CoV-2. On May 8, 2021, the Defence Research and Development Organisation (DRDO) announced that its anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) had been approved by the Drug Controller General of India (DCGI). Several studies, including those by Balakrishna et al. and Khurana et al., have highlighted the potential of 2-DG in mitigating COVID-19 through computational and in silico studies, with Bhatt et al. also supporting its use as a cost-effective adjuvant treatment.
(Read More in PDF Format)
Chapter 6 1634318-94-106